• Oncopeptides released initial data from its OP-701 INSULA window-of-opportunity trial in recurrent glioblastoma.
• Results have already been presented from the first three treated patients, with a fuller readout expected as enrollment continues.
• Tumor tissue analyses indicated the therapy crossed the blood-brain barrier, supporting the program’s core clinical proof-of-concept.
• Treatment was described as well tolerated so far, with no major drug-related toxicity reported in the evaluated patients.
• Recruitment continues toward about 10 patients to guide next development steps for the peptide drug conjugate platform in brain tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.